Our core product portfolio includes anti-idiotype antibody detection reagents, customized monitoring assays for CAR-T & TCR, and detection tools for dual CAR and other innovative CAR constructs. With abundant practical experience supporting First-In-Human investigator-initiated clinical trials (FIH IITs), CytoArt delivers flexible, rapid and dependable bioanalytical solutions to resolve bottlenecks in early-stage CGT development.
For R&D teams promoting cell therapy pipelines or struggling with immunogenicity evaluation challenges, our team welcomes on-site one-on-one technical consultation and customized solution discussion during WRIB 2025.